Insulet Co. (NASDAQ:PODD) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lifted its stake in Insulet Co. (NASDAQ:PODD) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 159,680 shares of the medical instruments supplier’s stock after purchasing an additional 3,354 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.23% of Insulet worth $41,688,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of PODD. Integrated Wealth Concepts LLC lifted its holdings in Insulet by 1.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after buying an additional 42 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after buying an additional 43 shares during the last quarter. Glenmede Trust Co. NA lifted its position in Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after acquiring an additional 47 shares during the period. Graypoint LLC grew its position in Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after buying an additional 47 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its stake in shares of Insulet by 4.7% during the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock worth $250,000 after acquiring an additional 48 shares during the period.

Insulet Trading Up 0.8 %

Shares of NASDAQ PODD opened at $285.34 on Tuesday. The company has a 50-day moving average of $270.65 and a two-hundred day moving average of $242.24. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market cap of $20.01 billion, a PE ratio of 48.86, a P/E/G ratio of 3.61 and a beta of 1.23.

Insider Buying and Selling

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

PODD has been the subject of several research analyst reports. Raymond James raised their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. BTIG Research raised their price target on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Wells Fargo & Company upped their price objective on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Sanford C. Bernstein began coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price on the stock. Finally, Morgan Stanley lifted their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $277.13.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.